Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688136.SS

STRONG SELLREMOVE

Kexing Biopharm Co., Ltd. · Healthcare · China · $626M · Avg Vol: $13M/d

12
StockRank
Q
47
V
34
M
17
P/E (TTM)
32.5x
ROE
6.4%
D/E
0.8x
Dividend %
1.3%
Director Trades · 180d
None in 180d →
Buybacks · 180d
$8.1M · 1d →
AI CONVICTION THESIS

Kexing Biopharm is a Chinese biopharmaceutical company. It lacks the global scale, regulatory validation, and multi-client diversification of a high-moat CDMO, making it a poor fit for our CDMO pricing power theme.

COMPANY DESCRIPTION

Kexing Biopharm Co., Ltd. specializes in the R&D, production, and sales of recombinant protein therapeutics and microecological preparations. The company maintains a strong competitive moat through its market-leading positions in recombinant human erythropoietin (EPO) and interferon, backed by an extensive commercialization network. It is an established biotechnology leader in China with a rapidly expanding footprint in emerging global markets.

FINANCIAL SUMMARY

Year2022202320242025CAGR
Revenue194M186M208M227M5.2%
EPS-0.07-0.140.020.12393.8%
Shares199M199M200M201M+1.3%
Debt153M165M180M206M10.4%
Equity267M240M242M259M-1.1%
Op CF-13M-13M16M13M-19.4%
Inv CF-56M-23M-15M-9M—
Fin CF55M2M-2M11M—
Loading...
PRICE (1M)-26.2%
2.723.023.323.623.92Apr 30May 26Jun 15
SMA 50SMA 200
Close
$2.74
RSI (14)
26.8
52W High
$9.32
From 52W High
0.3%

SCORE BREAKDOWN

Quality
47
ROIC
8.3%67.9
ROE
6.4%60.6
GP/Assets
25.4%57.5
Op. Margin
-1.4%34.2
FCF/Assets
-2.5%42.2
Piotroski
—55.8
Int. Cover
5.0x54.5
D/E Ratio
0.82x18.9
Current Ratio
1.50x24.6
Value
34
P/E (TTM)
32.5x34.1
EV/EBITDA
31.6x11.1
P/FCF
—N/A
P/B
2.1x53.3
P/S
2.6x60.9
Div Yield
1.3%36.1
Momentum
17
52W High %
29%5.1
RS 6M
-50%21.7
SMA 50/200
0.78x10.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$626M
P/E (Forward)
—
Gross Margin
61.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688136.SS are excluded.

TickerCompanyMkt CapStockRankSignal
688136.SSKexing Biopharm Co., Ltd.(you)$626M12STRONG SELL
300318.SZBeijing Bohui Innovation Biotechnology Group Co., Ltd.$613M12STRONG SELL
300149.SZChemPartner PharmaTech Co.,Ltd.$642M15STRONG SELL
688302.SSHinova Pharmaceuticals Inc.$582M14STRONG SELL
2105.HKLaekna, Inc.$666M15STRONG SELL
1167.HKJacobio Pharmaceuticals Group Co., Ltd.$490M12STRONG SELL
2591.HKGuangzhou Innogen Pharmaceutical Group Co., Ltd$648M7STRONG SELL
6955.HKShandong Boan Biotechnology Co., Ltd.$455M9STRONG SELL
688639.SSAnhui Huaheng Biotechnology Co., Ltd.$868M17STRONG SELL
2659.HKShanghai Bao Pharmaceuticals Co., Ltd.$1.0B10STRONG SELL

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%

Kexing Biopharm Co., Ltd. (688136.SS) — Stock Score Summary

Kexing Biopharm Co., Ltd. (688136.SS) has a MoatMap StockRank of 12/100 based on Quality (47/100), Value (34/100), and Momentum (17/100) factor scores. The current signal is STRONG SELL. Kexing Biopharm is a Chinese biopharmaceutical company. It lacks the global scale, regulatory validation, and multi-client diversification of a high-moat CDMO, making it a poor fit for our CDMO pricing power theme.

Kexing Biopharm Co., Ltd. specializes in the R&D, production, and sales of recombinant protein therapeutics and microecological preparations. The company maintains a strong competitive moat through its market-leading positions in recombinant human erythropoietin (EPO) and interferon, backed by an extensive commercialization network. It is an established biotechnology leader in China with a rapidly expanding footprint in emerging global markets.

Key Financial Metrics

Price$2.74
Market Cap$626M
P/E (TTM)32.53
Price/Book2.12
Return on Equity6.4%
Return on Invested Capital8.3%
Debt/Equity81.58
Gross Margin61.2%
Operating Margin-1.4%
Revenue Growth-20.7%
Dividend Yield1.3%
Free Cash Flow$-2M

Kexing Biopharm Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Kexing Biopharm Co., Ltd.’s (688136.SS) StockRank?
MoatMap’s StockRank for Kexing Biopharm Co., Ltd. (688136.SS) is 12/100, with a Strong Sell signal. It is a composite of Quality (47), Value (34), and Momentum (17) factor ranks across MoatMap’s 19,000+ stock universe.
Does Kexing Biopharm Co., Ltd. have an economic moat?
Kexing Biopharm Co., Ltd. (688136.SS) has a Quality factor score of 47/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Kexing Biopharm Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for Kexing Biopharm Co., Ltd. (688136.SS) is Strong Sell, based on a StockRank of 12/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Kexing Biopharm Co., Ltd. in?
Kexing Biopharm Co., Ltd. (688136.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).
Browse all ranked stocks688136.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock